{"id":"07638eda30e9","type":"article","url":"https://hartvaat.nl/2016/10/14/2016-esc-eas-richtlijn-voor-het-management-van-dyslipidemieen/","title":"2016 ESC/EAS-richtlijn voor het management van dyslipidemieën","title_en":"2016 ESC/EAS Guidelines for the Management of Dyslipidaemias.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["dyslipidemie","ezetimibe","ldl-cholesterol","lipidenverlaging","niet-statine-therapie","richtlijnen-esc","statines"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehw272","source_url":"https://doi.org/10.1093/eurheartj/ehw272","authors":["Alberico L Catapano","Ian Graham","Guy De Backer","Olov Wiklund","M John Chapman","Heinz Drexel","Arno W Hoes","Catriona S Jennings","Ulf Landmesser","Terje R Pedersen","Željko Reiner","Gabriele Riccardi","Marja-Riita Taskinen","Lale Tokgozoglu","W M Monique Verschuren","Charalambos Vlachopoulos","David A Wood","Jose Luis Zamorano","Marie-Therese Cooney"],"significance":10,"published":"2016-10-14","source_date":"2016-10-14","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/esc-richtlijn-dyslipidemie-2019/","https://hartvaat.nl/kennis/lipiden/ldl-cholesterol-mechanisme/"],"congress":"","summary_en":"The 2016 ESC/EAS Guidelines for dyslipidaemia management defined risk-stratified LDL-cholesterol targets and treatment strategies including high-intensity statins and emerging therapies such as PCSK9 inhibitors. This framework established the treat-to-target paradigm that underpins contemporary lipid-lowering practice.","created":"2026-07-03T10:26:22Z","updated":"2026-07-03T13:25:41Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"De ESC/EAS-richtlijn 2016 voor dyslipidemie — het standaardwerk dat streefwaarden en behandelstrategieën definieerde voor LDL-cholesterolverlaging. Introduceerde risicogecategoriseerde doelen en nieuwe medicamenteuze opties.","abstract_original":""}